ARTICLE | Translation in Brief
Blocking β cell destruction
How a first-in-class mAb could prevent Type I diabetes
April 9, 2015 7:00 AM UTC
Most attempts to develop therapies for Type I diabetes focus on regenerating pancreatic β cells or restoring their function. A group of researchers in Israel has developed a different approach by finding an antibody that blocks destruction of the insulin-producing β cells by suppressing NK cells.
BioLineRx Ltd. has licensed the compound and partnered with JHL Biotech Inc. to co-develop and commercialize a humanized version of the antibody, dubbed BL-9020...